We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multigene Test Extends Life Expectancy for Cancer Patients

By LabMedica International staff writers
Posted on 04 May 2017
Print article
Image: A histopathology of breast cancer:  intraductal carcinoma, noncomedo type, distended duct with intact basement membrane, micropapillary, and early cribriform growth pattern membrane and central tumor necrosis (Photo courtesy of Dr. Peter Abdelmessieh).
Image: A histopathology of breast cancer: intraductal carcinoma, noncomedo type, distended duct with intact basement membrane, micropapillary, and early cribriform growth pattern membrane and central tumor necrosis (Photo courtesy of Dr. Peter Abdelmessieh).
Testing for variants in seven cancer-associated genes, versus the usual process of testing in just two genes, followed by risk-reduction management could cost-effectively improve life expectancy for women at risk of hereditary breast cancer.

Breast cancer is the most commonly diagnosed non-cutaneous cancer and the second leading cause of cancer death among women in the USA. •n 2017, an estimated 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in the USA, along with 63,410 new cases of non-invasive (in situ) breast cancer. Women with a family history of breast cancer are at increased risk, with about 13% of women with breast cancer having one or more first-degree relatives with the disease.

Scientists at Quest Diagnostics investigate whether using a seven-gene test to identify women who should consider risk-reduction strategies could cost-effectively increase life expectancy. They estimated effectiveness and lifetime costs from a payer perspective for two strategies in two hypothetical cohorts of women (40-year-old and 50-year-old cohorts) who meet the National Comprehensive Cancer Network, defined family history criteria for multigene testing.

The two test strategies for detecting pathogenic genetic variants was: 1) the usual breast cancer 1, early onset, (BRCA1/2) test strategy, and 2) a Quest Diagnostics’ BRCAvantage Plus, next-generation seven gene strategy that tests for variants not only in BRCA1 and BRCA2, but also in Tumor protein p53 (TP53), Phosphatase and tensin homolog (PTEN), Cadherin-1 (CDH1), Serine/threonine kinase 11 (STK11), and Partner and localizer of BRCA2 (PALB2). Individuals who carry a pathogenic variant in any one of these genes are considered test-positive; otherwise, they are considered test-negative.

In the base-case scenario for 50- and 40-year-old women undergoing genetic testing, the incremental cost-effectiveness ratio (ICER) for the 7-gene test strategy compared with the BRCA1/2 test strategy was USD 42,067 and USD 23,734 per life-year gained, or USD 69,920 and USD 48,328 per quality-adjusted life-year gained, respectively. In probabilistic sensitivity analysis, the seven-gene test strategy cost less than $100,000 per life-year gained in 95.7% of the trials for the 50-year-old cohort.

Yonghong Li, PhD, the lead author of the study said, “Pathogenic variants in the BRCA1 and BRCA2 genes explain only about 15% of the breast cancer familial relative risk, while pathogenic variants in other genes, including TP53, PTEN, CDH1, and PALB2 contribute further to the familial relative risk. The results of this study demonstrate the potential value of newer testing options that allow for the simultaneous analysis of expanded panels of additional genes whose pathogenic variants confer moderate to high risk for breast cancer.” The study was published in the April 2017 issue of the journal Value in Health.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.